X

DIALOSA TABLET 2MG

Product Information

Registration Status: Active

SIN13675P

DIALOSA TABLET 2MG is approved to be sold in Singapore with effective from 2009-07-20. It is marketed by GOLDPLUS UNIVERSAL PTE LTD, with the registration number of SIN13675P.

This product contains Glimepiride 2mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by SPECIFAR S.A. in GREECE.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.

Indication

For concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.

Mechanism of Action

The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.

Pharmacokinetics

Absorption
Completely (100%) absorbed following oral administration.
Distribution
* 21.8 ± 13.9 L [Volunteers] * 19.8 ± 12.7 L [Patients with Type 2 diabetes, Single Dose] * 37.1 ± 18.2 L [Patients with Type 2 diabetes, Multiple Dose]
Metabolism
Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear.
Elimination

Clearance

* 52.1 +/- 16.0 mL/min [Normal subjects with single oral dose] * 48.5 +/- 29.3 mL/min [Patients with Type 2 diabetes, with single oral dose] * 52.7 +/- 40.3 mL/min [Patients with Type 2 diabetes, with multiple oral dose] * 47.8 mL/min [healthy after intravenous (IV) dosing]

Toxicity

Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.

Active Ingredient/Synonyms

Glimepirida | Glimépiride | Glimepiridum | Glimepiride |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!